Aravis has announced the appointment of three new members of the life science investment team.
Dr Dani Bach joins Aravis in February 2014 as Managing Partner within the life science team. Dani was previously part of the life sciences team at Geneva based venture fund, Index Ventures, having joined the firm in 2007.
Dani’s investment interests have focused on protein therapeutics, neurodegeneration, and medical devices. Prior to joining Index, Dani held a research position at the Ecole Polytechnique Federal de Lausanne (EPFL), where he worked on the complex interactions between human immunodeficiency virus (HIV) and the human immune system. Dani holds a PhD in Molecular Biology from the University of Barcelona.
Dr Jacques Mizrahi began consulting Aravis as a Venture Partner in mid-2013. Dr Mizrahi has over 20 years of experience in drug discovery, drug development and translational medicine for many large pharma companies including Roche where his last position was as an Executive Leader, Cardiovascular & Metabolic Diseases. He has a PhD in pharmacology from Sherbrooke University, Quebec Canada.
Dr Kadri Vunder joined Aravis’ life science team as a Partner mid-2013. Dr. Vunder has over 10 years investment and executive management experience in the biotech, chemical and financial industries. Prior to joining Aravis, Kadri built up and managed a biotechnology oriented seed investment firm LSVenture.
Kadri holds a PhD in Economics from the University of St. Gallen and scientific degrees from the Tallinn Technical University in Biotechnology and Analytical Chemistry.
Dr Simon Nebel, Founder and Managing Partner at Aravis said :“2014 will be an important year for us and we are excited to be starting it with the appointment of these high caliber team members. I am confident that their deep knowledge and proven expertise in the life science sector will be advantageous for Aravis’ future enterprises.”